Merck Drops Up to $610M on Neuro Disease-Focused Caraway Therapeutics

Merck bumped up its position from shareholder to acquirer in a move to scoop up neurodegenerative disease biotech Caraway Therapeutics for up to $610 million, the pharma giant announced Tuesday.